INNOVENT BIO (01801) opened more than 2% higher in Hong Kong trading, with shares climbing 2.48% to HKD 88.85 as of press time, recording a turnover of HKD 13.83 million.
According to a company announcement, INNOVENT BIO reported first-half product revenue exceeding RMB 8.2 billion, representing a year-on-year increase of more than 55%. In the second quarter alone, product revenue surpassed RMB 4.3 billion, up approximately 60% from the same period last year.
This robust performance underscores the sustained effectiveness of the company's "dual-engine" strategy. Core products such as Xinermei®, Xinbile®, and Xinbimin® have been standout performers, serving as key drivers of revenue growth.
Additionally, INNOVENT BIO has continued to strengthen its leadership position in the oncology segment. The market penetration of five tyrosine kinase inhibitors newly included in the National Reimbursement Drug List has been steadily rising, accelerating revenue expansion. The company has also made strides into the breast cancer treatment field, entering into a commercialization partnership with Eli Lilly for Verzenio® in mainland China. This collaboration lays the groundwork for further research, development, and market expansion in the breast cancer pipeline.
Comments